25 Results

Updated data from registration enabling NAVIGATOR trial of avapritinib for patients with PDGFRalpha, D842V-driven GIST and in second-, third- and fourth-line for other GIST patients. Blueprint Medicines

 Added 6 months ago

Blueprint Medicines Corporation announced updated data for the registration-enabling NAVIGATOR clinical trial of avapritinib, a potent and highly selective KIT...

Blueprint Medicines initiates Phase III trial of avapritinib to treat patients with advanced GIST.

 Added 11 months ago

Blueprint Medicines has dosed the first patient in the VOYAGER Phase III clinical trial, which is evaluating the safety and...

Induced pluripotent stem cells – a potential cancer vaccine

 Added 1 year ago

Induced pluripotent stem cells – a potential cancer vaccine

A new study from Stanford University may have found another use for iPS cells: priming the immune system to attack tumours.

World Cancer Day 2018

 Added 1 year ago

World Cancer Day 2018

UK NICE recommends use of Stivarga (regorafenib) in adults with gastrointestinal stromal tumours.- Bayer HealthCare.

 Added 1 year ago

The UK National Institute for Health and Care Excellence has backed Stivarga (regorafenib), from Bayer Healthcare, as a cost-effective option...

Successful Phase I trial of BLU 285 for gastrointestinal stromal tumors is basis for initiating Phase III trial in 2018.- BluePrint Medicines

 Added 1 year ago

Blueprint Medicines Corporation announced new Phase 1 clinical data and outlined registration plans for BLU 285, a potent and highly...

German Institute for Quality and Efficiency in Health Care suggests no additional benefit of Halaven (eribulin) in liposarcomas- Eisai

 Added 2 years ago

The German Institute for Quality and Efficiency in Health Care (IQWiG) has published a report which suggests that on formal...

Load more